TD Cowen analyst Itay Michaeli lowered the firm’s price target on Aptiv (APTV) to $93 from $108 and keeps a Buy rating on the shares. The firm updated its model following the spinoff of Verisagent and said its target is based on 10x 2026E EV/EBITDA, unchanged from prior sum-of=the parts valuation, and 15x P/E up from 10x blended previously.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTV:
- Aptiv Completes Spin-Off of Versigent, Realigning Portfolio
- Sixteen new option listings and two option delistings on April 1st
- Aptiv price target lowered to $93 from $95 at Wells Fargo
- Versigent to replace Titan International in S&P 600 at open on 4/2
- Aptiv price target lowered to $81 from $104 at RBC Capital